HSD17B6

Across TCGA pan-cancer cohorts, HSD17B6 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSD17B6 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher HSD17B6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSD17B6 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, GBM, and LUAD are the cancer types where HSD17B6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.659	0.885	.002	11	view →
GBM	OS	Median	All	0.364	0.770	.010	6	view →
LUAD	OS	Median	All	0.907	0.784	.020	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSD17B6–LSCC (DFS)

Open the LSCC breakdown →